User-defined outline with 11 sections.

Executive Summary

ZimPharma Manufacturing (Pvt) Ltd at a Glance

ZimPharma Manufacturing (Pvt) Ltd is a Harare-based pharmaceutical manufacturer producing affordable generic medicines for Zimbabwe’s private pharmacies, hospitals, clinics, wholesalers, and NGO health programmes. We manufacture essential tablets, capsules, syrups, and basic injectable formulations for chronic and acute treatment needs, with local production structured to reduce stock-outs, shorten lead times, and improve access to quality-assured medicines.

The business is led by In Year, Managing Director and Founder, a pharmacist with more than 10 years of experience in pharmaceutical distribution and hospital supply chains in Zimbabwe. The wider management team combines finance, operations, quality, sales, and formulation expertise through By Month, Casey Brooks, Reese Johansson, Morgan Kim, and Avery Singh, giving ZimPharma the technical and commercial depth required to launch and scale a regulated manufacturing operation.

At a glance

• Company: ZimPharma Manufacturing (Pvt) Ltd
• Location: Harare, Zimbabwe
• Legal structure: Private limited company
• Core products: Generic tablets, capsules, syrups, and basic injectables
• Year 1 revenue: USD 3,360,000
• Break-even timing: Month 1
• Year 5 revenue target: USD 5,612,302

The market gap we are solving

Zimbabwe remains heavily dependent on imported medicines, and that dependence keeps prices elevated while exposing buyers to long replenishment cycles and intermittent stock-outs. We are filling that gap with local manufacture to MCAZ-compliant and WHO GMP-aligned standards, built around consistent supply rather than opportunistic trading.

Our first product focus is on high-turnover essentials that move repeatedly through the market. That includes medicines for hypertension, diabetes, infections, pain, and basic institutional care, which are exactly the categories where buyers need predictable availability and stable pricing.

Why the opportunity is attractive

The addressable market includes more than 1,000 pharmacies and private or mission health facilities nationwide, plus wholesalers, distributors, and institutional buyers. We are targeting 150 to 200 active customers in Year 1 because that base is sufficient to support the operating model already reflected in the financial forecast.

:::reassure Why this is investable
Our commercial logic is simple and durable:

• local production reduces import exposure
• essential medicines generate repeat demand
• institutional buyers value batch traceability and fast replenishment
• Zimbabwe’s healthcare market rewards suppliers that can keep shelves and programmes stocked
  :::

The revenue engine and economics

ZimPharma makes money by selling finished generic medicines in bulk and contract formats to pharmacies, hospitals, clinics, wholesalers, and NGO buyers. A representative product such as amoxicillin 500 mg tablets is produced at a cost base that supports a 50.0% gross margin, giving us room to stay competitive while maintaining quality and compliance.

The Year 1 model is built around 40 major batches per month, with average monthly revenue of USD 280,000 and annual revenue of USD 3,360,000. That revenue profile is backed by a disciplined cost structure and a wide enough gross profit base to support marketing, quality control, and working capital needs without overextending the company.

Our longer-range target is to grow revenue to USD 5,612,302 by Year 5 through higher throughput, more active accounts, and a broader product mix. We are not relying on speculative demand. We are scaling from recurring procurement in a market where medicines are replenished continuously.

Headline financial position

Metric	Year 1	Year 3	Year 5
Revenue	USD 3,360,000	USD 4,102,560	USD 5,612,302
Gross Profit	USD 1,680,000	USD 2,051,280	USD 2,806,151
EBITDA	USD 720,000	USD 931,536	USD 1,500,082
Net Income	USD 454,860	USD 615,627	USD 1,059,122

The business reaches break-even at USD 2,163,000 in annual revenue, and the forecast shows break-even timing in Month 1 once full-scale production is live. That gives ZimPharma a strong operating cushion from the start of trading.

:::tip Investor takeaway
The model combines strong margin discipline with recurring demand. In practical terms, that means the company can service debt, absorb normal operating volatility, and still reinvest in product development and customer growth.
:::

Funding ask and capital structure

We are seeking USD 1,200,000 in total funding to complete production readiness, facility preparation, and early working capital support. The capital structure is deliberately balanced, with USD 900,000 in equity and USD 300,000 in medium-term debt at 12.5% over 5 years.

The funding is being used to launch a compliant pharmaceutical manufacturing platform in Harare with the equipment, systems, and inventory depth required to produce and release stock reliably. This structure gives ZimPharma enough liquidity to cover commissioning, validation, and the first customer ramp without compromising day-to-day operations.

:::warning Funding discipline matters
This capital raise is not for experimentation. It is to fund a production business that already has clear product economics, a defined customer base, and a five-year forecast built on repeatable batch sales.
:::

Why the plan is credible

The company is positioned to win on three fronts: supply reliability, regulatory confidence, and customer responsiveness. Reese Johansson, a pharmacist with 8 years in QA and regulatory affairs, protects MCAZ compliance and batch release discipline, while Casey Brooks, a chemical engineer with 9 years in pharmaceutical and food manufacturing, manages plant execution and throughput.

On the commercial side, Morgan Kim, a pharma sales professional with 10 years of experience across Southern Africa, drives direct B2B selling and account development, and Avery Singh, a formulation scientist with a master’s degree in pharmaceutics and 7 years of experience, anchors technical development and product transfer. Together with By Month, a chartered accountant with 12 years of experience in manufacturing finance and treasury, the team gives ZimPharma a balanced operating platform.

The result is a locally rooted pharmaceutical manufacturer with clear demand, strong economics, and measurable scale potential. We are building ZimPharma Manufacturing (Pvt) Ltd to become a dependable Zimbabwean source of essential generic medicines, with the financial capacity and operational discipline to grow from a launch-stage manufacturer into a nationally relevant supply partner.

Company Description

Legal Identity and Ownership

ZimPharma Manufacturing (Pvt) Ltd is a Zimbabwe-registered private limited company headquartered in Harare, Zimbabwe, within an industrial zone selected for its logistics access, utility reliability, and proximity to major distribution routes. We operate as a local pharmaceutical manufacturer focused on high-quality, affordable generic medicines for the Zimbabwean market.

The company was established to close a structural supply gap in essential medicines. Zimbabwe continues to depend heavily on imported pharmaceuticals, and that dependence creates high prices, long lead times, and recurring stock-outs for pharmacies, hospitals, clinics, and donor-funded programmes. ZimPharma Manufacturing (Pvt) Ltd addresses that gap by producing medicines locally under Medicines Control Authority of Zimbabwe compliance and WHO GMP-aligned standards.

Our legal structure is deliberately built for investment readiness and governance clarity. The founder holds majority shareholding in the business, while a minority stake is reserved for a strategic technical and financial partner. This structure protects operational control while allowing room for capital, technical expertise, and market access from a credible investor.

Ownership Position

• Majority ownership: Founder-controlled equity
• Minority ownership: Reserved for a strategic technical and financial partner
• Entity type: Private limited company
• Jurisdiction: Zimbabwe
• Regulatory alignment: MCAZ-compliant pharmaceutical manufacturer

This ownership model gives the business both agility and discipline. It allows us to make fast operating decisions while retaining enough flexibility to bring in a partner with manufacturing, regulatory, or distribution strength.

Our Mission and Commercial Purpose

Our mission is to manufacture reliable, affordable, and quality-assured generic medicines that improve access to essential treatment in Zimbabwe. We exist to replace uncertainty with dependable supply, and to do so at a price point that works for private buyers and institutional purchasers alike.

We manufacture tablets, capsules, syrups, and basic injectable formulations for common conditions including hypertension, diabetes, infections, and pain management. These are high-demand medicines with repeat purchasing patterns, which makes them commercially attractive and strategically important for public health continuity.

Our business is designed around practical outcomes for buyers. We reduce dependence on imported stock, shorten replenishment cycles, and create a more resilient pharmaceutical supply chain for Zimbabwe’s health sector.

:::reassure Why our model matters
ZimPharma Manufacturing (Pvt) Ltd is built on three investable strengths:

• Local production that reduces import dependence
• Essential medicines focus with repeat demand
• Regulatory discipline through MCAZ compliance and batch traceability
  :::

What We Manufacture and Why It Fits the Market

Our initial product mix is intentionally focused on high-turnover, essential generics. We are not trying to serve the market with a broad and expensive catalogue from day one. We are starting with products that have clear demand, measurable batch economics, and strong pull from pharmacies, hospitals, and procurement teams.

We supply to:

• Urban and peri-urban private pharmacies
• Private and mission hospitals
• Clinics and medical centres
• Wholesalers and distributors
• NGOs and public health programmes

These buyers need dependable supply, consistent quality, and responsive service. Our locally manufactured products are positioned to deliver all three.

A typical customer is a procurement manager, pharmacist, or medical superintendent who is responsible for stock availability and cost control. Our offer is tailored to that decision-maker’s reality: fewer stock-outs, shorter waiting periods, and better continuity of care.

Company Location and Operating Base

Our base in Harare gives us direct access to the country’s largest commercial and institutional medicine markets. It also supports efficient logistics into Bulawayo, Mutare, Gweru, and other major towns where pharmacy and hospital demand is concentrated.

The industrial-zone location supports our factory requirements. It provides better access to utilities, transport links, storage logistics, and vendor support than a non-industrial site would. That matters in pharmaceutical manufacturing, where environmental control, supply continuity, and distribution speed all affect operating performance.

We have structured the business to operate from a GMP-compliant facility with dedicated production, quality control, warehousing, and administrative functions. This layout supports batch integrity, quality segregation, and efficient movement of materials and finished goods.

Leadership and Operational Capability

The business is led by the founder, a pharmacist with more than 10 years of experience in pharmaceutical distribution and hospital-facing trade in Zimbabwe. That background gives ZimPharma Manufacturing (Pvt) Ltd direct insight into procurement behavior, product shortages, buyer expectations, and market pricing.

The wider team combines finance, operations, quality, sales, and formulation capability. Blake Morgan, a chartered accountant with 12 years of experience in manufacturing finance and treasury, leads financial control and funding discipline. Casey Brooks, a chemical engineer with 9 years of experience in pharmaceutical and food manufacturing, manages production planning and plant commissioning.

Reese Johansson, a pharmacist with 8 years in QA and regulatory roles, oversees quality assurance and regulatory affairs. Morgan Kim, a pharma sales professional with 10 years of experience across Southern Africa, leads business development and customer acquisition. Avery Singh, a formulation scientist with a master’s degree in pharmaceutics and 7 years of product development experience, leads technical development and scale-up.

This team structure gives the company strong control over the key functions that determine pharmaceutical manufacturing success: compliance, production consistency, market access, and cost discipline.

Positioning in the Zimbabwean Medicines Market

We are positioned as a local manufacturer of affordable, quality-assured generics for buyers that cannot afford unstable supply. Import-led competition remains strong, but it often comes with longer lead times, foreign exchange exposure, and delays linked to shipping and cross-border distribution.

Our value proposition is simple and commercially relevant:

• Lower supply risk through local production
• Faster delivery for urgent replenishment and tender response
• Competitive pricing because we reduce import logistics costs
• Quality assurance through batch traceability and regulatory oversight
• Direct customer support through an on-the-ground commercial team

We are not competing on novelty. We are competing on dependable access, documented quality, and pricing that makes sense for recurring procurement.

:::warning Investor relevance
Our business model depends on disciplined execution in the first year.

The key requirements are:

• Full MCAZ-compliant operations
• Reliable supply of raw materials and packaging
• Strong batch-level quality systems
• Consistent customer acquisition across pharmacies, hospitals, and institutional buyers
  :::

Founding Date and Growth Direction

ZimPharma Manufacturing (Pvt) Ltd was formed as a growth-stage industrial business with expansion built into the model from the start. Our first-year focus is establishing stable production, building customer relationships, and proving repeat order volume across Zimbabwe.

The next phase is capacity expansion, broader product development, and institutional contracting. By Year 3, we intend to have a broader product range and a stronger operational footprint. By Year 5, we aim to be a recognised local pharmaceutical manufacturing platform with regional partnership potential.

Our growth path is grounded in the realities of the local market. We are building from essential generics first, then expanding into more complex formulations as quality systems, demand visibility, and production efficiency mature.

Our Commitment to Zimbabwe’s Health Economy

ZimPharma Manufacturing (Pvt) Ltd is more than a factory business. It is a practical response to a national supply problem, designed to create local value, strengthen medicine security, and keep essential treatment within reach of the market that needs it most.

We serve institutions that cannot afford stock interruptions, and we do it with a business model that is commercially sound, regulatory aware, and scalable. That combination is what makes the company investable and operationally credible in Zimbabwe’s pharmaceutical manufacturing sector.

🔒 Continues in the full version

The remaining 9 sections of this document cover:

• Products and Services
• Market Analysis
• Competitive Analysis
• SWOT Analysis
• Marketing and Sales Strategy
• Management and Organization
• Operating Plan
• Financial Plan and Projections
• Funding Request

The full document is available below — click through for complete access.